Prophylactic and Therapeutic Antibodies (Q3)

Up until recently, most antibody therapeutics have been indicated for Inflammatory diseases and cancer. With the establishment of antibodies as therapeutics in these disease areas, there has been an expansion to a broader group of diseases such as infection, metabolic diseases, pain, Alzheimer, and bone diseases. With this expansion into new indications comes a new level of challenge. The meeting will address developing antibodies for prophylactic- or chronic-use indications that have traditionally been dominated by small molecule therapeutics, with case studies describing the development of antibodies for these market places; how molecule choices, dosing and delivery, and clinical design for efficacy and the minimization of safety risk all impact success. We will also address up and coming approaches such as antibody engineering for pharmacokinetic and pharmacodynamic improvements, the use of vaccines to induce humoral responses in vivo, and use of antibodies to deliver vaccines, as well as look back at what has been learned from chronic therapy of immune diseases. This meeting will be held in conjunction with the B cell meeting with an overlapping session on antibody diversity, as well as host workshops focusing on antibody specificity, crossing the blood braining barrier, and the use of smaller-bodies and polyclonal antibodies to address these new indications. It is anticipated that the attendees will come away with an appreciation of these challenges and that the meeting will stimulate research and novel solutions for addressing this group of indications.